Sign In
Buy NBTX
$39.15
-0.92 (-2.30%)
At Close: Jul 13, 2026
Nanobiotix: A Highly Speculative Bet On A Potential Radiotherapy Platform
05:46am, Thursday, 25'th Jun 2026
Nanobiotix is rated a strong speculative Buy, driven by risk-adjusted upside from its JNJ-1900 radioenhancer platform in partnership with Janssen. NBTX's lead indication, head and neck cancer, offers
Nanobiotix: A Royalty-Backed Physics Platform Hidden Inside A Biotech
04:58pm, Friday, 12'th Jun 2026
Nanobiotix is evolving into a capital-light, milestone- and royalty-driven oncology platform with JNJ-1900 at its core. JNJ-1900, now led by Johnson & Johnson, targets radioenhancement across multiple
Voting Rights and Shares Capital of the Company
04:15pm, Friday, 05'th Jun 2026
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) In accordance wi
Nanobiotix Provides First Quarter 2026 Operational and Financial Update
04:30pm, Tuesday, 02'nd Jun 2026
PARIS and CAMBRIDGE, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic app
Nanobiotix Joins the Euronext Tech Leaders Index
02:30am, Tuesday, 02'nd Jun 2026
PARIS and CAMBRIDGE, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic app
NANOBIOTIX Announces Closing of Global Offering
04:44pm, Tuesday, 26'th May 2026
PARIS and CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneer
PARIS and CAMBRIDGE, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneer
Nanobiotix Announces Pricing of Oversubscribed €85m Global Offering
10:57am, Thursday, 21'st May 2026
PARIS, France and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company
Nanobiotix Announces Trading Resumption of Its Ordinary Shares on Euronext Paris
09:30am, Thursday, 21'st May 2026
PARIS and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneer
Nanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext Paris
02:30am, Thursday, 21'st May 2026
PARIS and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneer
Nanobiotix Announces Launch of Global Follow-On Offering
06:19pm, Wednesday, 20'th May 2026
PARIS and CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneer
How Nanobiotix Got Wall Street's Attention By Using Physics To Battle Cancer
08:00am, Wednesday, 20'th May 2026
Nanobiotix wants to fundamentally change a century-old mainstay in battling cancer. The top-notch biotech stock is flying.
Data presented by Johnson & Johnson at the 2026 European Society for Radiotherapy and Oncology (ESTRO) Annual Meeting Data presented by Johnson & Johnson at the 2026 European Society for Radiotherapy
Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study
05:29pm, Monday, 04'th May 2026
PARIS and CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-b
Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Given Average Rating of “Moderate Buy” by Analysts
04:22am, Friday, 24'th Apr 2026
Shares of Nanobiotix S.A. - Sponsored ADR (NASDAQ: NBTX - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the five analysts that are currently covering the company, Ma
